Skip to Content

Enzon to Present Preclinical Data On HIF-1alpha antagonist at AACR

Company will host informative reception

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) will be presenting Inhibition of HIF-1alpha antagonist from in vitro and in vivo studies on Sunday, April 13, at the 2008 American Association for Cancer Research (AACR) meeting in San Diego, California.

On Monday, April 14, Enzon will host a cocktail reception from 6:30pm – 7:30pm in the Point Loma Room at the San Diego Marriott Hotel & Marina. This reception is an opportunity to hear some additional insight regarding Enzon’s HIF-1alpha antagonist program.

Due to limited space, please RSVP to Carole Imperiale at 908-541-8678 or

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon’s PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company’s revenue base. Further information about Enzon and this press release can be found on the Company’s web site at

Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777
EVP, Finance and Chief Financial Officer


Posted: April 2008